Paracentesis before intravitreal injection of bevacizumab.
Tsui
Yung-Ping
YP
Chiang
Chun-Chi
CC
Tsai
Yi-Yu
YY
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000867:Anterior Chamber / Q000601:surgery*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D008269:Macular Edema / Q000150:complications / Q000188:drug therapy; D009798:Ocular Hypertension / Q000517:prevention & control; D019152:Paracentesis / Q000379:methods*; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab